IMS Health — Q1 2015 Earnings Presentation
21 slides from IMS Health's earnings presentation, Apr 24, 2015
Slide 1: IMS Health Q1 2015 Earnings Call
IMS Health Q1 2015 Earnings Call April 24, 2015 IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 2: Legal
Legal This presentation should be viewed in conjunction with IMS Health’s Q1 2015 earnings call Safe Harbor Statement This presentation includes “forward-looking statements”, including statements regarding future financial and operating results, especially those set forth under the heading “Full-Yea
Slide 3: 1st Quarter Results
1st Quarter Results $M Revenue EBITDA +7 0% +7.0% +9 8% +9.8% @ CFx @ CFx $632 $645 $216 $ $217 $ Q1 2015 Q1 2014 Q1 2015 Q1 2014 Note: Dollars are actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as defined in the IMS Health earnings release IMS Health Confidenti
Slide 4: Cegedim - Deal Closed, onto Integration
Cegedim - Deal Closed, onto Integration Integrated Solutions Focus Areas Reference database Market information Go to market Integrate products Marketing Compliance Social Media Sales Performance Leverage resources IMS Health Confidential. Do not distribute outside your organization. 4 (c) 2015 IMS
Slide 5: 1st Quarter Offering Revenue
1st Quarter Offering Revenue Offering 1st Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Information $354 $381 3.0% (7.0%) Technology Services $278 $264 12.7% 5.3% Total $632 $645 7.0% (2.0%) Note: Dollars are actual foreign exchange rates IMS Health Confidential. Do not distribut
Slide 6: 1st Quarter Geographic Revenue
1st Quarter Geographic Revenue Geography 1st Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Developed Markets $522 $532 6.1% (1.8%) Emerging Markets $110 $113 11.2% (2.9%) Total $632 $645 7.0% (2.0%) Note: Dollars are actual foreign exchange rates IMS Health Confidential. Do not d
Slide 7: 1st Quarter EBITDA
1st Quarter EBITDA 1st Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Adjusted EBITDA (1) $216 $217 9.8% (0.5%) Adjusted EBITDA 34.2% 33.7% 87 bps 49 bps margin g Note: Dollars are actual foreign exchange rates (1) See reconciliations of non-GAAP items in appendix IMS Health Confi
Slide 8: 1st Quarter P&L
1st Quarter P&L At reported FX rates $M (except per share data) 2015 2014 Net Income / (Loss) $298 ($24) Diluted Earnings / (Loss) per Share $0.86 ($0.09) Adjusted Net Income (1) $136 $70 Adjusted Diluted Earnings per Share (1) $0.39 $0.24 (1) See reconciliations of non-GAAP items in appendix IMS He
Slide 9: 1st Quarter Balance Sheet Items & Metrics
1st Quarter Balance Sheet Items & Metrics $M 2015 2014 Cash & Cash Equivalents $639 $390 (1) Principal Balance of Debt (2) $3,969 $3,816 (1) Net Debt $3,330 $3,426 (1) Gross Leverage Ratio 4.5x 4.3x (1) Net Cash (Used in) Provided by $30 ($103) Operating Activities Capital Expenditures and Additions
Slide 10: Cegedim Historical Quarterly Phasing
Cegedim Historical Quarterly Phasing Average phasing Q2 Q3 Q4 Total Q2 – Q4 2013-2014 Revenue 30% 30% 40% 100% EBITDA 20% 25% 55% 100% IMS Health Confidential. Do not distribute outside your organization. 10 (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 11: Foreign Currency Movement Since January 2014
Foreign Currency Movement Since January 2014 Euro and Yen Euro 0% Yen (10%) ~15% Decline (20%) ~20% Decline Jan Jun Dec Mar 2014 2014 2014 2015 Note: Exchange rates are as of month-end Source: Central Bank of Italy IMS Health Confidential. Do not distribute outside your organization. 11 (c) 2015 IMS
Slide 12: 2nd Quarter Guidance
2nd Quarter Guidance Revenue Q1 2015 Actual Q2 2015 Guidance (1) Constant Currency Growth 7.0% 25 - 26% Fx Impact (9.0%) (14%) Reported Growth (2.0%) 11 - 12% (2) Adjusted j EBITDA Q1 2015 Actual Q Q2 2015 Guidance (1) Q Constant Currency Growth 9.8% 8 - 9% Fx Impact (10.3%) (14%) Reported Growth (0
Slide 13: Full-Year 2015 Guidance
Full-Year 2015 Guidance Core IMS IMS w/Acquisition (1) Constant Currency Constant Currency Reported (2) Revenue Growth 5 - 6% 19 - 20% ~10% Adjusted EBITDA 7.5 - 8.5% 13 - 14% ~4% Growth Adjusted Net Income Growth 16 - 19% 20 - 23% 8 - 11% Adjusted Diluted 11 - 14% 15 - 18% 4 - 6% EPS Note: Bold num
Slide 14: Q&A
Q&A IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 15: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures IMS Health Confidential. (c) 2015 IMS Health Incorporated. All Rights Reserved.
Slide 16: Net Income to Adjusted EBITDA
Net Income to Adjusted EBITDA Three Months Ended March 31, (in millions) 2015 2014 Net Income (Loss) $ 298 $ (24) B Benefit fi from f income i taxes (240) (13) Other (income) loss, net (4) 17 Interest expense 37 89 Interest income — (2) Depreciation and amortization 96 107 Deferred revenue purchase
Slide 17: Net Income to Adjusted Net Income & Per Share Data
Net Income to Adjusted Net Income & Per Share Data Three Months Ended March 31, (in millions, except per share data) 2015 2014 Net Income (Loss) $ 298 $ (24) Benefit from income taxes (240) (13) Amortization associated with purchase accounting 62 76 Deferred revenue purchasing accounting adjustments
Slide 18: Unlevered Free Cash Flow
Unlevered Free Cash Flow Three Months Ended March 31, (in millions) 2015 2014 Net Cash Provided by (Used in) Operating Activities $ 30 $ (103) Capital expenditures (9) (33) Additions to computer software (23) (21) Free Cash Flow $ (2) $ (157) Cash interest payments 30 102 Cash tax Cas a pay payments
Slide 19: Gross Leverage Ratio
Gross Leverage Ratio (in millions) Gross Debt as of March 31, 2015 $ 3,969 Adj t d EBITDA ffor th Adjusted the year ended d dDDecember b 3131, 2014 878 Less: Adjusted EBITDA for the three months ended March 31, 2014 (217) Add: Adjusted EBITDA for the three months ended March 31, 2015 216 Adjusted EB
Slide 20: Non-GAAP Adjustments By Income Statement Line Items
Non-GAAP Adjustments By Income Statement Line Items Three Months Ended March 31, (in millions) 2015 2014 Non-GAAP adjustments included in: Operating costs of information, exclusive of depreciation and amortization 1 4 Direct and incremental costs of technology services, exclusive of depreciation 1 3
Slide 21: END
END IMS Health Confidential. Do not distribute outside your organization. 21 (c) 2015 IMS Health Incorporated. All Rights Reserved.